M-A | Agonistas receptores de GLP-1 reduzem eventos cardiovasculares adversos maiores, mortalidade por todas as causas, admissão hospitalar por insuficiência cardíaca e piora na função renal em pacientes com diabetes tipo 2.

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Conteúdo relacionado: Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.